An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04151719

Enrollment

Registered

2019-11-05

Start date

2020-02-03

Completion date

2024-02-03

Last updated

2021-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled in Study SAL-REL-2042 (NCT04083651).

Interventions

DRUGMethylnaltrexone bromide (MNTX)

Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult participants greater than or equal to (≥)18 years of age on the date the Informed Consent Form (ICF) is signed, with the capacity to provide voluntary informed consent. * Enrolled in double-blind Study SAL-REL-2042 (NCT04083651) and completed an end of study (EOS) visit (Day 168) or completed Day 56 of the Study SAL-REL-2042 (NCT04083651). * Must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB)-approved ICF and provide authorization, as appropriate, for local privacy regulations. * Willing and able to comply with scheduled visits, the treatment plan, and laboratory tests. * Signed an informed consent/Health Insurance Portability and Accountability Act (HIPAA) form.

Exclusion criteria

* Concurrent therapy with any other investigational agent during the study. * Current use of a peripherally acting mu-opioid-receptor antagonist. * Current evidence of untreated brain metastasis(es). * Diarrhea greater than Grade 1, based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0). * Bowel obstruction. * Advanced liver disease. * Renal disease. * Any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Principal Investigator, would make the participant inappropriate for the study.

Design outcomes

Primary

Measure	Time frame
Overall Survival	From first MNTX dose administration until death from any cause (up to 4 years)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026